← Back to Clinical Trials
Recruiting NCT06103916

NCT06103916 Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06103916
Status Recruiting
Phase
Sponsor Maxima Medical Center
Condition Ovarian Tumor
Study Type OBSERVATIONAL
Enrollment 613 participants
Start Date 2022-07-15
Primary Completion 2027-08

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 613 participants in total. It began in 2022-07-15 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Multicenter prospective cohort study in which patients ≥18 years with an ovarian tumor for which an ultrasound has been performed in accordance with IOTA criteria and the IOTA ADNEX model has been applied are included. Ultrasound data from these patients will be prospectively recorded in a database to determine the diagnostic accuracy of the IOTA ADNEX model in Dutch gynaecological practice.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years 2. Presence of a complex ovarian tumor 3. Ultrasound assessment in accordance with IOTA definitions and application of the ADNEX model 4. Understanding of Dutch language Exclusion Criteria: 1. Women with an ovarian tumor that meets the IOTA criteria of a benign easy descriptor: 1. Unilocular tumor with ground glass echogenicity in premenopausal woman suggestive of endometrioma 2. Unilocular tumor with mixed echogenicity and acoustic shadows in premenopausal women (suggestive of benign cystic teratoma) 3. Unilocular tumor with regular walls and maximal diameter \< 10cm (suggestive of simple cyst or cystadenoma) 4. Remaining unilocular tumors with regular walls 2. Histologically proven malignancy prior to ultrasound

Contact & Investigator

Central Contact

Esther Lems, MD

✉ PRIORITY@mmc.nl

📞 +31 40 888 83 80

Frequently Asked Questions

Who can join the NCT06103916 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Ovarian Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06103916 currently recruiting?

Yes, NCT06103916 is actively recruiting participants. Contact the research team at PRIORITY@mmc.nl for enrollment information.

Where is the NCT06103916 trial being conducted?

This trial is being conducted at Veldhoven, Netherlands.

Who is sponsoring the NCT06103916 clinical trial?

NCT06103916 is sponsored by Maxima Medical Center. The trial plans to enroll 613 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology